Previous studies in human cancer have shown that the blockade of PD-L1 with monoclonal antibodies enhances the destruction of cytotoxic T-lymphocyte-mediated tumour cells and improves the activation of antigen presentation and cytokine release, suggesting a putative potential as a therapeutic target [82,83]. This evidence concerns the gene CD274 and cancer.